Clincosm LogoSign in Get a demo

A Relative Bioavailability Study of Peresolimab (LY3462817) Formulations in Healthy Participants

Sponsor
Eli Lilly and Company (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05959109
Collaborator
(none)
56
Enrollment
1
Location
4
Arms
5.1
Anticipated Duration (Months)
11
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main purpose of this study is to look at the amount of the study drug, peresolimab, that gets into the blood stream and how long it takes the body to get rid of it when given under the skin using test formulations versus reference formulation in healthy participants. The study will also evaluate the safety and tolerability of peresolimab and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately up to 17 weeks, including screening.

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
56 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
A Phase 1, Single-Dose Study to Assess the Relative Bioavailability and Tolerability of Subcutaneous Peresolimab Test Formulations in Healthy Participants
Anticipated Study Start Date :
Jul 19, 2023
Anticipated Primary Completion Date :
Dec 21, 2023
Anticipated Study Completion Date :
Dec 21, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Peresolimab (Test 1)

Peresolimab administered subcutaneously (SC).

Drug: Peresolimab
Administered SC
Other Names:
  • LY3462817

    		•
    Experimental: Peresolimab (Test 2)

    Peresolimab administered SC.

    Drug: Peresolimab
    Administered SC
    Other Names:
  • LY3462817

    		•
    Experimental: Peresolimab (Test 3)

    Peresolimab administered SC.

    Drug: Peresolimab
    Administered SC
    Other Names:
  • LY3462817

    		•
    Experimental: Peresolimab (Reference)

    Peresolimab administered SC.

    Drug: Peresolimab
    Administered SC
    Other Names:
  • LY3462817

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Peresolimab [Predose up to 85 days postdose]

      PK: Cmax of Peresolimab

    2. PK: Area Under the Plasma Concentration Versus Time Curve from Zero to T, Last Time Point (AUC[0-tlast]) of Peresolimab [Predose up to 85 days postdose]

      PK: AUC[0-tlast] of Peresolimab

    3. PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Peresolimab [Predose up to 85 days postdose]

      PK: AUC(0-∞) of Peresolimab

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Male and female participants who are overtly healthy as determined by medical history, physical examination, and other screening procedures

    • A minimum body weight of 45 kilograms and body mass index (BMI) between 18.0 and 32.0 kilograms per meter squared (kg/m²), inclusive, at screening

    • Have blood pressure, pulse rate, blood and urine laboratory test results that are acceptable for the study

    • Males who agree to use highly effective/effective methods of contraception and women not of childbearing potential

    Exclusion Criteria:

    • Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, of constituting a risk when taking the study intervention, or of interfering with the interpretation of data

    • Have a history of allergy to monoclonal antibody therapy or to the excipients in the drug formulation, or have clinically significant intolerance to topical corticosteroids, or a history of severe posttreatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear IgA dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis).

    • Have a diagnosis or history of malignant disease within 5 years prior to screening, with the following exceptions:

    1. basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years

    2. cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to screening.

    • Are immunocompromised.

    • Have known hypogammaglobulinemia

    • Have a current or recent acute, active infection. For at least 30 days before screening and up to the baseline visit, participants must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment.

    • Have had any of the following types of infection within 3 months prior to the screening visit or develops any of these infections before the baseline visit:

    1. serious (requiring hospitalization, or IV or equivalent oral antibiotic treatment, or both)

    2. opportunistic (as defined in Winthrop et al. 2015)

    3. chronic (duration of symptoms, signs, and/or treatment of 6 weeks or longer)

    4. recurring (including, but not limited to, herpes simplex, herpes zoster, recurring cellulitis, chronic osteomyelitis).

    • Have active TB.

    • Have or have had latent tuberculosis infection that has not been treated with a complete course of appropriate therapy as defined by the World Health Organization and the United States Centers for Disease Control and Prevention, unless such treatment is underway.

    • Have a current infection with HBV (that is, positive for hepatitis B surface antigen and/or polymerase chain reaction positive for HBV DNA).

    • Have a current infection with HCV (that is, positive for HCV RNA).

    • Have HIV infection.

    • Have received treatment with biologic agents (such as monoclonal antibodies, including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing.

    • Have received any live vaccine (that is, live attenuated) within less than 4 weeks before screening or intend to receive a live vaccine during the study, or within 5 half-lives (8 weeks) after receiving the last dose of study intervention, whichever is longer. Note: The following are not considered live vaccines: RNA vaccines, vaccines with inactive viral elements, and/or nonreplicating viral vector vaccines.

    • Have received a bacille Calmette-Guerin vaccination or treatment within less than 4 weeks before screening or intend to receive bacille Calmette-Guerin vaccination or treatment during the study, or within 5 half-lives (8 weeks) after receiving the last dose of study intervention, whichever is longer.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 LabCorp CRU, Inc Dallas Texas United States 75247

    Sponsors and Collaborators

    • Eli Lilly and Company

    Investigators

    • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Eli Lilly and Company
    ClinicalTrials.gov Identifier:
    NCT05959109
    Other Study ID Numbers:
    • 18608
    • J1A-MC-KDAI
    First Posted:
    Jul 25, 2023
    Last Update Posted:
    Jul 25, 2023
    Last Verified:
    Jul 15, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Jul 25, 2023